2015 November 11

Leukos Biotech, a spin-off established by Dr. Ruth Risueño and the IJC to develop a new treatment for acute myeloblastic leukaemia (AML) up and running

Dr. Ruth Risueño and her team have identified the potential of a current medicine marketed for the treatment of Parkinson's disease, as a possible new effective treatment for the cure of AML.

The group has discovered that treatment with this drug has an anti-leukaemia effect on the cells of patients with AML ex vivo. Furthermore, treatment of mice carrying human leukaemia leads to the elimination of the capacity for regeneration of the leukaemia in vivo. The amount of drug used corresponds to that approved for use in humans. In fact, the treatment of both ex vivo and in vivo healthy blood samples does not affect its efficacy or its endurance.